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Autophagy is an important cellular homeostasis pathway, but its role in cancer remains to be fully elucidated.
In this issue of Cancer Cell, Hall and colleagues describe a TRPM3-dependent autophagy pathway that is
selectively important for clear cell renal cell carcinoma and can be effectively inhibited.Autophagy is a highly conserved homeo-
static mechanism for the degradation
and recycling of bulk cytoplasm, organ-
elles, and long-lived proteins through the
lysosomal machinery. Given its role in
cellular homeostasis, it is not surprising
that autophagy has been found to be
deregulated in many human diseases,
including cancer (Schneider and Cuervo,
2014). However, how autophagy contrib-
utes to cancer ontogenesis and progres-
sion has turned out to be more complex
than expected. Overall, the emerging
concept is that autophagy has both
positive and negative effects, depending
on the tumor stage. While functional auto-
phagy prevents tumor initiation, its pro-
survival effect may allow transformed
cells to resist against adverse conditions.
Consistently, several studies demon-
strated that different autophagy-related
genes play a central role in tumorigenesis
by controlling tumor growth and/or tumor
suppression (Guo et al., 2013; Takahashi
et al., 2007). Further, more recent evi-
dence highlighted the existence of addi-tional roles besides autophagy regulation
for autophagy-related factors. Indeed,
the key pro-autophagic molecule Beclin
1 may also act in vacuolar protein sorting
and the degradation of specific growth
factor receptors (Funderburk et al., 2010).
More recently, a role for Beclin 1-medi-
ated autophagy in the regulation of cancer
cell growth induced by the epidermal
growth factor receptor has also been
demonstrated (Wei et al., 2013). Such
multiple roles for autophagy regulators
may reflect the need for an integrated
regulation of metabolic homeostasis.
One hypothesis about the impact of
autophagy on cancer is that autophagy-
deficient cells accumulate malfunctioning
proteins and organelles, leading to reac-
tive oxygen species production, DNA
damage, chromosomal instability, and
activation of oncogenes. Another possi-
bility is that autophagy plays a negative
role in the control of cell proliferation.
Indeed, mice with monoallelic deletion of
Becn1 or Bif1 display a hyperproliferative
phenotype (Qu et al., 2003; Takahashiet al., 2007). On the other hand, in a
cancer that develops in the absence
of any recognizable autophagy defects,
autophagy acts as an effective pro-
survival process for cancer cells to
sustain metabolic distress, react to pro-
death stimuli, and circumvent nutrient
deficiency. Along this line, autophagy
represents a metabolic ‘‘addiction’’ for a
successful cancer cell (Guo et al., 2013).
As a consequence of this duality for
cancer-related autophagy, the develop-
ment of cancer therapies targeting auto-
phagy is still very preliminary. Indeed,
although the inconsiderate inhibition of
autophagy may be beneficial for the
treatment of well-established tumors, it is
potentially dangerous to the patients’
health. Therefore, generally disturbing
the autophagy machinery or the auto-
phagosome/autophagolysosome func-
tion should be avoided. In fact, it has
beendescribed that autophagy deficiency
is responsible for tumorigenesis as well as
defects in a plethora of other physiological
processes (Schneider and Cuervo, 2014).ovember 10, 2014 ª2014 Elsevier Inc. 599
Figure 1. Ions-Mediated Autophagy as a Novel Molecular Target in
Cancer
Hall et al. (2014) describe a novel autophagy pathway important in ccRCC,
centered on the ion channel TRPM3. The possible strategies to manipulate
this pathway at several steps are indicated in red. The molecules’ labels are
indicated in the text.
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have to be addressed in order
to move autophagy inhibitors
to cancer treatment is their
selectivity to tumors com-
pared to normal tissues. In
this issue of Cancer Cell, Hall
et al. (2014) report a careful
characterization of an auto-
phagy pathway that only
occurs in clear cell renal cell
carcinoma (ccRCC) and is
important to tumor growth
(Figure 1). They found that
the Transient Receptor Po-
tential Melastatin 3 (TRPM3)
modulates autophagy by
regulating the calcium influx,
which in turn regulates
CAMKK2.Thissignalingcross
talkswith known factors of the
autophagy network, such as
the kinases AMPK and ULK1.
In addition, TRPM3 modu-
lates autophagy through
regulating the zinc influx and
the level of miR-214, whichtargets the autophagosome adaptor LC3.
Finally, the authors show that mefenamic
acid, a TRPM3 inhibitor in clinical use,
limits the growth of xenografts of von Hip-
pel-Lindau tumor suppressor (VHL)-defi-
cient ccRCC cells.
Interestingly, ions (calcium and zinc)
and microRNAs (miR-204 and miR-214)
are among the main players in the path-
way of autophagy induction described
here (Hall et al., 2014). These molecules,
by impacting on both autophagosome
formation and TRPM3 recycling through
caveolin (Figure 1), could hopefully be
targeted without a complete shut-off
of physiological levels of autophagy.
Therefore, they provide selective thera-
peutic targets for ccRCCwithout affecting
autophagy elsewhere, thus sparing the
healthy tissues. Ions and microRNAs
are interesting biological targets; chemi-
cal chelating agents and miRNA mimics
have been described as promising
methods to modulate ions and miRNAs,
respectively, in cancer treatment and600 Cancer Cell 26, November 10, 2014 ª20other pathologies (Henry et al., 2011;
Seely et al., 2005). In sum, Hall et al.
(2014) describe a detailed molecular
network for autophagy induction upon
mutation of the VHL oncogene frequently
occurring in ccRCC. Obviously, compo-
nents of this novel network of regulation
would also be relevant as diagnostic
markers.
Of note, a role for autophagymodulation
in VHL-loss induced tumors had been
described and a potential drug, STF-
62247, selective for ccRCC was identified
(Chan andGiaccia, 2008). STF-62247was
shown to selectively target VHL-deficient
cancer cells by inducing ‘‘autophagic cell
death,’’ but no autophagy flux was mea-
sured at that time, raising doubts on this
interpretation (Chan and Giaccia, 2008).
With the present existing tools for auto-
phagy measurements and in light of
Hall and colleagues’ findings, it would
be worthy to investigate whether STF-
62247’s effect is also mediated by
miRNAs and ions regulations or through14 Elsevier Inc.a different autophagy path-
way. These results are particu-
larly interesting, because tem-
sirolimus and everolimus, both
mTOR inhibitors that signifi-
cantly induce autophagy, are
in clinical use for the treat-
ment of advanced renal cell
carcinoma.
Much work still remains to
develop the strategies to treat
cancers by manipulating au-
tophagy, from reliable moni-
toring levels of autophagy in
human samples and pharma-
codynamics to identification
of new targets and effective
drugs, but the finding by Hall
et al. (2014) may represent
a turning-page step toward
this goal.REFERENCES
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